CO2019005165A2 - Compuesto de piridona como inhibidor de c-met - Google Patents
Compuesto de piridona como inhibidor de c-metInfo
- Publication number
- CO2019005165A2 CO2019005165A2 CONC2019/0005165A CO2019005165A CO2019005165A2 CO 2019005165 A2 CO2019005165 A2 CO 2019005165A2 CO 2019005165 A CO2019005165 A CO 2019005165A CO 2019005165 A2 CO2019005165 A2 CO 2019005165A2
- Authority
- CO
- Colombia
- Prior art keywords
- met inhibitor
- pyridone compound
- compound
- pyridone
- met
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
En la presente invención se describe un tipo de compuestos de piridona como inhibidores de c-met, y se describe específicamente un compuesto como se muestra en la fórmula (I) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610954377 | 2016-10-27 | ||
| PCT/CN2017/107964 WO2018077227A1 (zh) | 2016-10-27 | 2017-10-27 | 作为c-MET抑制剂的吡啶酮类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019005165A2 true CO2019005165A2 (es) | 2019-05-31 |
Family
ID=62024383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0005165A CO2019005165A2 (es) | 2016-10-27 | 2019-05-21 | Compuesto de piridona como inhibidor de c-met |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10501443B2 (es) |
| EP (1) | EP3533787B1 (es) |
| JP (1) | JP6719679B2 (es) |
| KR (1) | KR102070748B1 (es) |
| CN (1) | CN109311812B (es) |
| AU (1) | AU2017348810B2 (es) |
| BR (1) | BR112019008415B1 (es) |
| CA (1) | CA3041164C (es) |
| CO (1) | CO2019005165A2 (es) |
| DK (1) | DK3533787T3 (es) |
| EA (1) | EA038108B1 (es) |
| ES (1) | ES2835301T3 (es) |
| HR (1) | HRP20201985T1 (es) |
| HU (1) | HUE051734T2 (es) |
| IL (1) | IL266126B (es) |
| LT (1) | LT3533787T (es) |
| MX (1) | MX374439B (es) |
| MY (1) | MY189557A (es) |
| PE (1) | PE20190912A1 (es) |
| PH (1) | PH12019500875B1 (es) |
| PL (1) | PL3533787T3 (es) |
| PT (1) | PT3533787T (es) |
| RS (1) | RS61126B1 (es) |
| SG (1) | SG11201903801YA (es) |
| SI (1) | SI3533787T1 (es) |
| UA (1) | UA122737C2 (es) |
| WO (1) | WO2018077227A1 (es) |
| ZA (1) | ZA201903074B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465986B2 (en) * | 2018-04-26 | 2022-10-11 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor |
| US11442063B2 (en) * | 2018-05-30 | 2022-09-13 | Promega Corporation | Broad spectrum kinase binding agents |
| US12122780B2 (en) | 2019-02-01 | 2024-10-22 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor |
| WO2022022687A1 (zh) * | 2020-07-31 | 2022-02-03 | 南京明德新药研发有限公司 | 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法 |
| WO2022063869A2 (en) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| US20240277711A1 (en) | 2021-06-04 | 2024-08-22 | Merck Patent Gmbh | Compounds for the treatment of glioblastoma |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002002519A2 (en) * | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
| CN1930126A (zh) | 2004-03-05 | 2007-03-14 | 万有制药株式会社 | 吡啶酮衍生物 |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2013057101A1 (de) * | 2011-10-17 | 2013-04-25 | Bayer Intellectual Property Gmbh | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| EP2827872A1 (en) * | 2012-03-19 | 2015-01-28 | Merck Patent GmbH | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds |
| KR102157501B1 (ko) * | 2012-10-11 | 2020-09-18 | 메르크 파텐트 게엠베하 | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 ｍｅｋ 억제제와의 조합 |
| CA2970394C (en) * | 2014-12-11 | 2023-03-14 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative |
-
2017
- 2017-10-27 AU AU2017348810A patent/AU2017348810B2/en active Active
- 2017-10-27 JP JP2019540379A patent/JP6719679B2/ja active Active
- 2017-10-27 MY MYPI2019002142A patent/MY189557A/en unknown
- 2017-10-27 SI SI201730558T patent/SI3533787T1/sl unknown
- 2017-10-27 HU HUE17864813A patent/HUE051734T2/hu unknown
- 2017-10-27 CN CN201780036464.XA patent/CN109311812B/zh active Active
- 2017-10-27 RS RS20201448A patent/RS61126B1/sr unknown
- 2017-10-27 CA CA3041164A patent/CA3041164C/en active Active
- 2017-10-27 PL PL17864813T patent/PL3533787T3/pl unknown
- 2017-10-27 LT LTEP17864813.5T patent/LT3533787T/lt unknown
- 2017-10-27 HR HRP20201985TT patent/HRP20201985T1/hr unknown
- 2017-10-27 US US16/343,387 patent/US10501443B2/en active Active
- 2017-10-27 SG SG11201903801YA patent/SG11201903801YA/en unknown
- 2017-10-27 EA EA201990952A patent/EA038108B1/ru unknown
- 2017-10-27 KR KR1020197014236A patent/KR102070748B1/ko active Active
- 2017-10-27 DK DK17864813.5T patent/DK3533787T3/da active
- 2017-10-27 MX MX2019004626A patent/MX374439B/es active IP Right Grant
- 2017-10-27 PH PH1/2019/500875A patent/PH12019500875B1/en unknown
- 2017-10-27 WO PCT/CN2017/107964 patent/WO2018077227A1/zh not_active Ceased
- 2017-10-27 PT PT178648135T patent/PT3533787T/pt unknown
- 2017-10-27 BR BR112019008415-0A patent/BR112019008415B1/pt active IP Right Grant
- 2017-10-27 PE PE2019000855A patent/PE20190912A1/es unknown
- 2017-10-27 EP EP17864813.5A patent/EP3533787B1/en active Active
- 2017-10-27 UA UAA201904417A patent/UA122737C2/uk unknown
- 2017-10-27 ES ES17864813T patent/ES2835301T3/es active Active
-
2019
- 2019-04-18 IL IL266126A patent/IL266126B/en active IP Right Grant
- 2019-05-16 ZA ZA2019/03074A patent/ZA201903074B/en unknown
- 2019-05-21 CO CONC2019/0005165A patent/CO2019005165A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR108768A2 (es) | Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| AR101995A1 (es) | COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6 | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| CR20170574A (es) | Compuestos antifíngicos | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| CR20190310A (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX2017006110A (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| AR104241A1 (es) | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |